WHO ICTRP trial
Viral clearance, PK and tolerability of ensovibep in COVID-19 patients
EUCTR2021-000365-33-NL · EU Clinical Trials Register · Authorised
Key facts
| Trial ID | EUCTR2021-000365-33-NL |
|---|---|
| Public title | Viral clearance, PK and tolerability of ensovibep in COVID-19 patients |
| Scientific title | A Phase 2a open label, non-comparative, single dose escalation study to evaluate the dynamics of viral clearance, pharmacokinetics and tolerability of ensovibep in patients with symptomatic COVID-19 disease |
| Primary sponsor | Molecular Partners AG |
| Registry | EU Clinical Trials Register |
| Recruitment status | Authorised |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Netherlands |
| Conditions | SARS-CoV-2 infection (COVID-19) MedDRA version: 23.0 Level: PT Classification code 10084268 Term: COVID-19 System Organ Class: 10021881 - Infections and infestations ;Therapeutic area: Diseases [C] - Virus Diseases [C02] |
| Interventions | Product Name: Ensovibep Product Code: MP0420 Pharmaceutical Form: Solution for infusion INN or Proposed INN: Ensovibep Current Sponsor code: MP0420 Other descriptive name: DARPin targeting three different epitopes of SARS-CoV-2… |
| Registration date | Feb 3, 2021 |
| Target size | 40 |
| Secondary IDs | CHDR2043;MP0420-CP204 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: